Arens, AM et al. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol (Phila). 2017 Jul 13:1-7.
Beaver KM, Gavin TJ. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med. 1998 Sep; 16(5):505-7.
Buck ML and Reed MD. Use of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients. J Clin Pharm. 1991 Jan;10(1):32-48.
Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000 Apr; 35(4):374-81.
Dawson, Andrew H., and Nicholas A. Buckley. Pharmacological Management of Anticholinergic Delirium ‐ Theory, Evidence and Practice. British Journal of Clinical Pharmacology 81.3 (2016): 516–524. PMC. Web. 18 Sept. 2017.
Hail SL, Obafemi A, Kleinschmidt KC. Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient. Clin Toxicol (Phila). 2013 Mar; 51(3):162-6.Knapp S, Wardlow ML, Albert K et al.: Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects. Drug Metab Dispos.1991;19:400–404.Pentel, P and Peterson, CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980 Nov;9(11):588-90.
Rosenbaum, Christopher, and Steven B. Bird. “Timing and Frequency of Physostigmine Redosing for Antimuscarinic Toxicity.” Journal of Medical Toxicology 6.4 (2010): 386–392. PMC. Web. 18 Sept. 2017.
Phillips, Michelle A. et al. Use of a Physostigmine Continuous Infusion for the Treatment of Severe and Recurrent Antimuscarinic Toxicity in a Mixed Drug Overdose. Journal of Medical Toxicology 10.2 (2014): 205–209. PMC. Web. 18 Sept. 2017.
Schneir AB, Offerman SR, Ly BT, Davis JM, Baldwin RT, Williams SR, Clark RF. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med 2003; 42: 14–9.
Suchard, JR. Assessing physostigmine's contraindication in cyclic antidepressant ingestions. J Emerg Med. 2003 Aug;25(2):185-91.
Triggle, DJ. Mitchell, JM, and Filler, R. The pharmacology or physostigmine. CNS Drug Reviews, Vol. 4, No. 2, 1998. 87-136.
Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME. The Use of Physostigmine by Toxicologists in Anticholinergic Toxicity. J Med Toxicol. 2015 Jun; 11(2):179-84.
Stout BJ, Hoshide R, Vincent DS. Takotsubo Cardiomyopathy in the Setting of Acute Alcohol Withdrawal. Hawai’i Journal of Medicine & Public Health. 2012;71(7):193-194.
Peng TJ, Patchett ND, Bernard SA. Takotsubo Cardiomyopathy and Catatonia in the Setting of Benzodiazepine Withdrawal. Case Reports in Cardiology. 2016;2016:8153487. doi:10.1155/2016/8153487.
Spadotto V, Zorzi A, ElMaghawry M, Meggiolaro M, Pittoni GM. Heart failure due to “stress cardiomyopathy”: a severe manifestation of the opioid withdrawal syndrome. European Heart Journal Acute Cardiovascular Care. 2013;2(1):84-87. doi:10.1177/2048872612474923.
Authored by: Russell Trigonis, MD
EM Rotators on Toxicology
Selected by Feedspot as one of the Top 20 Toxicology Blogs on the web
Disclaimer: All images included on this blog are the sole property of CMC EM Residency and cannot be used or reproduced without written permission. Patient identifiers have been redacted/changed or patient consent has been obtained. Information contained in this blog is the opinion of the author and application of material contained in this blog is at the discretion of the practitioner to verify for accuracy.